In yesterday’s Wall Street session, BioCardia Inc. (NASDAQ:BCDA) shares traded at $0.94, down -11.68% from the previous session.
As of this writing, 2 analysts cover BioCardia Inc. (NASDAQ:BCDA). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $4.00, we find $4.00. Given the previous closing price of $1.07, this indicates a potential upside of 273.83 percent. BCDA stock price is now 123.57% away from the 50-day moving average and -37.93% away from the 200-day moving average. The market capitalization of the company currently stands at $20.43M.
There are 1 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $4.00 as their price target over the next twelve months.
In other news, Altman Peter, President and CEO bought 6,200 shares of the company’s stock on May 26. The stock was bought for $9,920 at an average price of $1.60. Upon completion of the transaction, the President and CEO now directly owns 469,239 shares in the company, valued at $0.44 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 16, 10% Owner FROST PHILLIP MD ET AL bought 595,238 shares of the business’s stock. A total of $1,000,000 was incurred on buying the stock at an average price of $1.68. This leaves the insider owning 2,025,827 shares of the company worth $1.9 million. Insiders disposed of 73,009 shares of company stock worth roughly $68628.45999999999 over the past 1 year. A total of 53.49% of the company’s stock is owned by insiders.
Wednesday morning saw BioCardia Inc. (NASDAQ: BCDA) opened at $1.0600. During the past 12 months, BioCardia Inc. has had a low of $0.36 and a high of $2.92. The fifty day moving average price for BCDA is $0.4318 and a two-hundred day moving average price translates $1.5149 for the stock.
The latest earnings results from BioCardia Inc. (NASDAQ: BCDA) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.12, inline with analysts’ expectations of -$0.12. This compares to -$0.17 EPS in the same period last year. The net profit margin was -2197.72% and return on equity was -728.95% for BCDA. The company reported revenue of $0.36 million for the quarter, compared to $0.21 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 68.4 percent. For the current quarter, analysts expect BCDA to generate $90k in revenue.
BioCardia Inc.(BCDA) Company Profile
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.